Trial Profile
A Pilot Study of Crizotinib in Patients With c-MET Positive Gastric Adenocarcinoma as a Third-line Chemotherapy
Status:
Completed
Phase of Trial:
Phase II
Latest Information Update: 06 Nov 2021
Price :
$35
*
At a glance
- Drugs Crizotinib (Primary)
- Indications Adenocarcinoma; Gastric cancer
- Focus Therapeutic Use
- 16 Feb 2017 Status changed from recruiting to completed.
- 13 May 2015 New trial record